Introduction and medication guidance of capmatinib

Capatinib (Capatinib), as an innovative oral, selectivec-Met kinase inhibitor, has demonstrated excellent clinical efficacy in the field of lung cancer treatment in recent years, especially for patients with METex14 mutations in non-small cell lung cancer (NSCLC). It was developed by the Swiss pharmaceutical company Novartis and successfully launched on the market, providing new treatment options and hope for many lung cancer patients around the world.

Capmatinib has a unique mechanism of action. By specifically inhibitingc-Met kinase activity, it effectively blocks the growth signaling pathway of tumor cells, thereby inhibiting the proliferation and spread of tumor cells. This is undoubtedly a major therapeutic breakthrough for patients who carry METex14 mutations. Clinical trial data show that capmatinib performs well in prolonging patient survival and improving quality of life.

However, as a prescription drug, capmatinib must be used strictly as directed by your doctor. Before taking medication, patients should fully understand the indications, usage and dosage, and possible adverse reactions of the medication, and inform the doctor of their allergies, medication history, and other medications currently being used to avoid the risk of drug interactions.

The recommended dose of capmatinib is usually 400 mg taken orally twice daily (i.e. two 200 mg tablets) before or after meals. Patients should swallow the tablets whole and do not crush, cut or chew the tablets to avoid affecting the absorption and efficacy of the medicine. If you forget to take the medicine or vomit after taking the medicine, it is generally not recommended to take it again, but to continue taking the medicine at the next scheduled time.

In addition, patients should pay close attention to their physical condition during medication. If adverse reactions such as nausea, vomiting, diarrhea, rash, etc. occur, they should report to the doctor in time. The doctor may adjust the drug dosage or change the treatment plan according to the patient's specific condition to ensure the safety and effectiveness of the treatment.

Finally, it should be emphasized that although capmatinib is effective, it is not suitable for all patients with lung cancer. Patients should formulate individualized treatment plans under the guidance of doctors, and remain patient and actively cooperate during the treatment process to obtain the best treatment results.